J. Prins

发表

The many different faces of major depression: it is time for personalized medicine.

H. Hendriksen, R. Oosting, S. Korte, 2015, European journal of pharmacology.

The 5‐HT1A/1B‐receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and “waiting” impulsivity, but increases “stopping” impulsivity

O. Güntürkün, D. Denys, R. Oosting, 2017, European journal of pharmacology.

The Novel Triple Reuptake Inhibitor JZAD-IV-22 Exhibits an Antidepressant Pharmacological Profile without Locomotor Stimulant or Sensitization Properties

A. Kozikowski, S. Korte, Afshin Ghavami, 2010, Journal of Pharmacology and Experimental Therapeutics.

Environmental Enrichment Induces Behavioral Recovery and Enhanced Hippocampal Cell Proliferation in an Antidepressant-Resistant Animal Model for PTSD

Berend Olivier, H. Hendriksen, R. Oosting, 2010, PloS one.

On the origin of allostasis and stress-induced pathology in farm animals: celebrating Darwin's legacy.

C. Vinkers, S. Korte, B. Olivier, 2009, Veterinary journal.

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited

S. Korte, B. Olivier, J. Prins, 2011, Expert opinion on investigational drugs.

Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: An intracranial self-stimulation study

A. Kraneveld, S. Korte, S. Korte, 2013, Brain, Behavior, and Immunity.

Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice

A. Kraneveld, S. Korte, B. Olivier, 2013, Behavioural Brain Research.

The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats

S. Korte, B. Olivier, K. Westphal, 2011, Pharmacology Biochemistry and Behavior.

The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.

R. Schreiber, D. Denys, S. Korte, 2010, European journal of pharmacology.

Lipopolysaccharide increases degradation of central monoamines: an in vivo microdialysis study in the nucleus accumbens and medial prefrontal cortex of mice.

A. Kraneveld, S. Korte, B. Olivier, 2014, European journal of pharmacology.

The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats.

R. Schreiber, P. Kenny, B. Olivier, 2012, European journal of pharmacology.

The many different faces of major depression: it is time for personalized medicine.

H. Hendriksen, R. Oosting, S. Korte, 2015, European journal of pharmacology.